In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion in Spanish about perioperative chemotherapy and immunotherapy and how recent research may affect clinical decision making in Latin America.

Guest: Dr. Clarissa Baldotto graduated from the Fluminense Federal University and studied Clinical Oncology at the National Cancer Institute (INCA). She completed a Master's Degree in Clinical Cancerology at INCA and a PhD in Medical Sciences at the D'Or Institute for Research and Education (ID'Or).

Guest: Dr. Paula Ugalde Figueroa graduated from the School of Medicine at the Federal University of Bahia in Salvador, BA, Brazil. With training in Brazil, the United States, and Canada, Dr. Ugalde has established herself as a research-driven thoracic surgeon. In 2021, she was appointed as a Director of the IASLC Board of Directors and continues to break barriers for many Latinas in oncology.

Seminal Trial Series: Crizotinib in PROFILE 1001 by IASLC

Lung Cancer Considered in Farsi.

LCC In Greek by IASLC

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and two esteemed oncology colleagues discuss an evolving hot topic: the use of immune checkpoint inhibitors in the treatment of patients with molecular driven non-small cell lung cancer.

Guest: Dr. Erin Schenk is an Assistant Professor of Medicine in the section of Medical Oncology at the University of Colorado and the Director of the Schenk Laboratory

X: @SchenkLab

Guest: Dr. Biagio Ricciuti is a Thoracic Medical Oncologist and Data Scientist at Dana-Farber Cancer Institute and Harvard Medical School

X: @BiagioRicciutMD

In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion on the management of early-stage disease, with an eye toward applying conclusions from trials such as the ADAURA and the recent ESMO and ELCC data about perioperative chemo-immunotherapy.

Description: Host Dr. Narjust Florez and two esteemed international clinicians discuss the unique characteristics of CNS metastases in patients with non-small cell lung cancer and small cell lung cancer.

Guest: Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at Yale

Guest: Dr. Ernest Nadal is a medical oncologist and the director of Thoracic Tumors Section at the Catalan Institute of Oncology, an Associate Professor at the University of Barcelona, a vital member of the Spanish Lung Cancer Group and an expert in clinical trial development and interest in response and use of immune checkpoint inhibitors for the management of CNS metastases.

Continuing our series of podcasts in different world languages, this episode focuses on lung cancer research and treatment in Romanian.

Host: Mihaela Aldea, MD PhD

Thoracic Oncology and Precision Medicine Group

Department of Medical Oncology

Gustave Roussy, Villejuif, France

Guest: Dr Cristina Ligia Cebotaru, Institute of Oncology 'Prof Dr Ion Chiricuta' Department of Radiotherapy-Medical Oncology, Cluj Napoca

Guest: Dr. Paul Kubelac, Department of Medical Oncology, Institute of Oncology Cluj-Napoca-Romania

Biomarkers are essential in lung cancer treatment, but they remain underutilized. In addition, clinicians and patients have to wait for those results before starting therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu guides a discussion about biomarkers and some of the challenges and issues they create.

This episode of Lung Cancer Considered discusses first-line treatment options for EGFR mutant NSCLC, in Italian.

Guest: Dr. Jessica Menis is a thoracic medical oncologist with expertise in early-phase trials and drug development from Azienda Ospedaliera Universitaria Integrata Verona. Jessica, welcome to the podcast.

Guest: Professor Filippo de Marinis is from Istituto Europeo di Oncologia, where he is Direttore della Divisione di Oncologia Toracica, and the president of Associazione Italiana Oncologia Toracica.